Literature DB >> 33907996

Glycosylation of Therapeutic Proteins: A Critical Quality Attribute.

Arnaud Delobel1.   

Abstract

Glycosylation is a common posttranslational modification of therapeutic proteins. The glycosylation pattern is dependent on many parameters such as the host cell line or the culture conditions. N- and O-linked glycans usually play a great role on the stability, safety, and efficacy of the drug. For this reason, glycosylation is considered as a critical quality attribute of therapeutic glycoproteins, and a thorough characterization should be performed, as well as a systematic control for each batch produced. This chapter gives a short presentation of the structure of glycans commonly found on recombinant therapeutic proteins, and their role on the properties of the drug, in terms of stability, pharmacokinetics, safety, and efficacy. Lastly, the use of mass spectrometry for the analysis of glycoproteins is briefly described.

Entities:  

Keywords:  Critical quality attribute; Glycoprotein; Glycosylation; Immunogenicity; Mass spectrometry; Monoclonal antibody; Pharmacokinetics

Year:  2021        PMID: 33907996     DOI: 10.1007/978-1-0716-1241-5_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  73 in total

Review 1.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database.

Authors:  R Apweiler; H Hermjakob; N Sharon
Journal:  Biochim Biophys Acta       Date:  1999-12-06

Review 2.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

Review 3.  PNGases as valuable tools in glycoprotein analysis.

Authors:  Ting Wang; Josef Voglmeir
Journal:  Protein Pept Lett       Date:  2014       Impact factor: 1.890

Review 4.  Determination of critical quality attributes for monoclonal antibodies using quality by design principles.

Authors:  Nadja Alt; Taylor Y Zhang; Paul Motchnik; Ron Taticek; Valerie Quarmby; Tilman Schlothauer; Hermann Beck; Thomas Emrich; Reed J Harris
Journal:  Biologicals       Date:  2016-07-25       Impact factor: 1.856

Review 5.  Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis.

Authors:  M M Goldenberg
Journal:  Clin Ther       Date:  1999-01       Impact factor: 3.393

Review 6.  Therapeutic monoclonal antibody N-glycosylation - Structure, function and therapeutic potential.

Authors:  Florian Cymer; Hermann Beck; Adelheid Rohde; Dietmar Reusch
Journal:  Biologicals       Date:  2017-11-26       Impact factor: 1.856

7.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics.

Authors:  T S Raju; J B Briggs; S M Borge; A J Jones
Journal:  Glycobiology       Date:  2000-05       Impact factor: 4.313

Review 8.  Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system.

Authors:  Susan A Brooks
Journal:  Mol Biotechnol       Date:  2004-11       Impact factor: 2.695

Review 9.  Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.

Authors:  Anshu Kuriakose; Narendra Chirmule; Pradip Nair
Journal:  J Immunol Res       Date:  2016-06-29       Impact factor: 4.818

10.  Mapping the O-glycoproteome using site-specific extraction of O-linked glycopeptides (EXoO).

Authors:  Weiming Yang; Minghui Ao; Yingwei Hu; Qing Kay Li; Hui Zhang
Journal:  Mol Syst Biol       Date:  2018-11-20       Impact factor: 11.429

View more
  3 in total

1.  Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells.

Authors:  Lisa Strasser; Stefano Boi; Felipe Guapo; Nicholas Donohue; Niall Barron; Alana Rainbow-Fletcher; Jonathan Bones
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

2.  The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab.

Authors:  Haiyan Jia; Parvathy Harikumar; Eleanor Atkinson; Peter Rigsby; Meenu Wadhwa
Journal:  Biomolecules       Date:  2021-10-30

3.  In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis.

Authors:  Dinko Šoić; Zvonimir Mlinarić; Gordan Lauc; Olga Gornik; Mislav Novokmet; Toma Keser
Journal:  Front Chem       Date:  2022-10-03       Impact factor: 5.545

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.